The goal of this research study is to test if ciltacabtagene autoleucel (cilta-cel) is safe
and effective in treating participants with high-risk, smoldering myeloma.
The names of the treatment interventions used in this study are:
- Cilta-cel (or chimeric antigen receptor T cells)
- Cyclophosphamide (a lymphodepleting chemotherapy)
- Fludarabine (a lymphodepleting chemotherapy)